Nicolet Advisory Services LLC Grows Position in Repligen Co. (NASDAQ:RGEN)

Nicolet Advisory Services LLC grew its stake in Repligen Co. (NASDAQ:RGEN) by 6.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,254 shares of the biotechnology company’s stock after acquiring an additional 201 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Repligen were worth $452,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in RGEN. Andra AP fonden acquired a new position in Repligen in the 2nd quarter valued at about $25,000. Lazard Asset Management LLC grew its holdings in shares of Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after buying an additional 130 shares in the last quarter. Blue Trust Inc. raised its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new position in shares of Repligen during the second quarter valued at approximately $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

RGEN opened at $142.58 on Friday. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The firm has a market cap of $7.99 billion, a price-to-earnings ratio of -385.34, a PEG ratio of 4.27 and a beta of 0.96. The company has a current ratio of 10.44, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The company has a fifty day simple moving average of $140.26 and a 200 day simple moving average of $143.44.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the business posted $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. Equities research analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on RGEN shares. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.